Virtual event: CAR-T comes of age?

Editor’s note: A livestream of this event is embedded below.

It’s been almost a decade since the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it. Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that? STAT gathers experts to look ahead.

Featured speakers:


  • Sponsor Introduction: Anshul Mangal, president, Project Farma and Precision ADVANCE
  • Daina Graybosch, Ph.D., senior research analyst at SVB Leerink
  • Adam Feuerstein, senior writer, biotech, STAT (moderator) 

[embedded content]

Source: STAT